Publication: HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)
Submitted Date
Received Date
Accepted Date
Issued Date
2011-09-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
17921015
17920981
17920981
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-79960267925
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 767-770
Citation
Kiyoshi Kikuchi, Hisaaki Uchikado, Naoki Miura, Yoko Morimoto, Takashi Ito, Salunya Tancharoen, Kei Miyata, Rokudai Sakamoto, Chiemi Kikuchi, Narumi Iida, Naoto Shiomi, Terukazu Kuramoto, Naohisa Miyagi, Ko Ichi Kawahara (2011). HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review). Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/11484.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Series
Has Part
Abstract
Historically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB1 plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant.